NYSEAMERICAN:RGNT Regentis Biomaterials Q2 2026 Earnings Report $1.81 0.00 (0.00%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$1.82 +0.01 (+0.55%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Regentis Biomaterials EPS ResultsActual EPS-$0.22Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARegentis Biomaterials Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARegentis Biomaterials Announcement DetailsQuarterQ2 2026Date9/11/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Regentis Biomaterials Earnings HeadlinesRegentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Significant Growth in Short InterestSeptember 19 at 3:22 AM | americanbankingnews.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.September 18 at 10:15 AM | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.September 21 at 1:00 AM | Porter & Company (Ad)Regentis Biomaterials (NYSEAMERICAN:RGNT) Shares Down 0.6% - Should You Sell?September 17, 2026 | americanbankingnews.comRegentis Biomaterials (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage RepairSeptember 14, 2026 | markets.businessinsider.comRegentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage RepairSeptember 14, 2026 | finance.yahoo.comSee More Regentis Biomaterials Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Regentis Biomaterials? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regentis Biomaterials and other key companies, straight to your email. Email Address About Regentis BiomaterialsRegentis Biomaterials (NYSEAMERICAN:RGNT) is an Israel-based medical device company developing biomaterial technologies for the treatment of cartilage injuries and other orthopedic conditions. The company focuses on regenerative solutions intended to support the repair of damaged tissue while reducing the need for more invasive procedures. Its lead product is GelrinC, a synthetic, cell-free hydrogel implant designed for the treatment of focal cartilage defects in the knee. The product is placed arthroscopically and forms a scaffold intended to integrate with surrounding tissue and support the regeneration of hyaline-like cartilage. Regentis Biomaterials operates as a clinical-stage company, with activities centered on product development, clinical evaluation, regulatory advancement and potential commercialization of its orthopedic biomaterial platform. The company is headquartered in Israel and is pursuing opportunities in international healthcare markets.View Regentis Biomaterials ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to GrowthThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big Move Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
